Chronic kidney disease (CKD), Nephrotic syndrome
Conditions
Interventions
1. To add tolvaptan 15mg/day to the conventional therapy 2. Not to change other treatments after the start of tolvaptan for one week
Sponsors
Toyama University Hospital
Saiseikai Toyama Hospital Saiseikai Takaoka Hospital Toyama Rosai Hospital Kamiichi General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with kidney diseases treated with sodium-excreting diuretics 2. Patients satisfying the Framingham criteria for congestive heart failure 3. Patients who have ability to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients under 20 years of age at time of enrolling 2. Serum Na >=145 mEq/L 3. Patients with difficulty in water intake 4. Anuria 5. Patients with severe liver failure or severe congestive heart failure 6. Others deemed ineligible for this trial by physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Efficacy of tolvaptan (changes in urine volume, body weight and inferior vena cava diameter) 2. Indices of efficacy of tolvaptan (urine osmotic pressure, urinary aquaporin 2/ plasma vasopressin ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Renal function after administration of tolvaptan 2. Side effects of tolvaptan | — |
Countries
Japan
Contacts
Public ContactTsutomu Koike
Toyama University Hospital The Second Department of Internal Medicine
Outcome results
None listed